RECEIVED
CENTRAL FAX CENTER
MAY 24 2007

Amendments to the Claims:

The following Listing of Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-20. (Canceled)

21. (Currently amended) A pharmaceutical composition comprising a Toll-like receptor 8 (TLR8) agonist that comprises a 2-aminopyridine fused to a five membered nitrogen-containing heterocyclic ring in an amount effective to modulate at least one TLR8-mediated cellular signaling pathway in combination with a pharmaceutically acceptable carrier, wherein the TLR8 agonist comprises a substituted imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolonaphthyridine amine, a thiazolonaphthyridine amine, a 6-, 7-, 8-, or 9-aryl or heteroaryl substituted imidazoquinoline amine, a 1*H*-imidazo dimer fused to a pyridine amine, quinoline amine, tetrahydroquinoline amine, naphthyridine amine, or tetrahydronaphthyridine amine, a purine derivative, an imidazoquinoline amide derivative, an imidazopyridine derivatives, a benzimidazole derivative, a derivative of a 4-aminopyrimidine fused to a five membered nitrogen containing heterocyclic ring, or a 3-β-D-ribofuranosylthiazolo[4,5-*d*]pyrimidine derivative.

22-29. (Canceled)

30. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a substituted imidazoquinoline amine.

31. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a tetrahydroimidazoquinoline amine.

32. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is an imidazopyridine amine.

33. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a 1,2-bridged imidazoquinoline amine.

34. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a 6,7-fused cycloalkylimidazopyridine amine.

35. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is an imidazonaphthyridine amine.

36. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a tetrahydroimidazonaphthyridine amine.

37. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is an oxazoloquinoline amine.

38. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a thiazoloquinoline amine.

39. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is an oxazolopyridine amine.

40. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a thiazolopyridine amine.

41. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is an oxazolonaphthyridine amine.

42. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a thiazolonaphthyridine amine.

43. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a 6-, 7-, 8-, or 9-aryl or heteroaryl substituted imidazoquinoline amine.

44. (Previously presented) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a 1*H*-imidazo dimer fused to a pyridine amine, quinoline amine, tetrahydroquinoline amine, naphthyridine amine, or tetrahydronaphthyridine amine.